Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
Calicivirus, Feline
/ drug effects
Electrophoresis, Polyacrylamide Gel
Genome, Viral
/ drug effects
Hemagglutination Tests
Humans
Influenza A virus
/ drug effects
Microscopy, Electron, Transmission
Norovirus
/ drug effects
Plant Extracts
/ pharmacology
Plants, Medicinal
Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2
Saxifragaceae
Viral Proteins
/ drug effects
SARS-CoV-2
Saxifraga spinulosa
medicinal herb
pandemic
pyrogallol-enriched fraction
virus disinfectant
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
28 06 2020
28 06 2020
Historique:
received:
23
05
2020
revised:
21
06
2020
accepted:
26
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
21
7
2020
Statut:
epublish
Résumé
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus (IAV), and norovirus (NV) are highly contagious pathogens that threaten human health. Here we focused on the antiviral potential of the medicinal herb, Saxifraga spinulosa (SS). Water-soluble extracts of SS were prepared, and their virus-inactivating activity was evaluated against the human virus pathogens SARS-CoV-2 and IAV; we also examined virucidal activity against feline calicivirus and murine norovirus, which are surrogates for human NV. Among our findings, we found that SS-derived gallocatechin gallate compounds were capable of inactivating all viruses tested. Interestingly, a pyrogallol-enriched fraction (Fr 1C) inactivated all viruses more rapidly and effectively than did any of the component compounds used alone. We found that 25 µg/mL of Fr 1C inactivated >99.6% of SARS-CoV-2 within 10 s (reduction of ≥2.33 log
Identifiants
pubmed: 32605306
pii: v12070699
doi: 10.3390/v12070699
pmc: PMC7411974
pii:
doi:
Substances chimiques
Antiviral Agents
0
Plant Extracts
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K16397
Pays : International
Organisme : Japan Society for the Promotion of Sciences
ID : 19K07212
Pays : International
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Antiviral Res. 2005 Nov;68(2):66-74
pubmed: 16137775
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Emerg Infect Dis. 2020 Jul;26(7):1592-1595
pubmed: 32284092
J Nat Prod. 1996 Feb;59(2):205-15
pubmed: 8991956
J Nat Prod. 2017 Sep 22;80(9):2416-2423
pubmed: 28832147
Clin Microbiol Infect. 2014 Aug;20(8):724-30
pubmed: 24943671
Food Environ Virol. 2020 Mar;12(1):9-19
pubmed: 31620998
PLoS One. 2019 Apr 23;14(4):e0215822
pubmed: 31013314
Viruses. 2015 Sep 14;7(9):4929-44
pubmed: 26389935
BMC Public Health. 2016 May 12;16:396
pubmed: 27175786
Biol Pharm Bull. 2002 Jan;25(1):19-23
pubmed: 11824550
Antiviral Res. 1993 Aug;21(4):289-99
pubmed: 8215301
Phytochemistry. 2006 Sep;67(17):1849-55
pubmed: 16876833
Br J Pharmacol. 2013 Mar;168(5):1059-73
pubmed: 23072320
J Occup Med Toxicol. 2008 Nov 13;3:26
pubmed: 19014531
Am J Ther. 2007 Sep-Oct;14(5):455-61
pubmed: 17890935
Molecules. 2018 Jul 20;23(7):
pubmed: 30037024
Curr Opin Virol. 2014 Oct;8:22-9
pubmed: 24866471
Antivir Chem Chemother. 2005;16(6):393-8
pubmed: 16329286
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Microbiol Immunol. 2009 Sep;53(9):531-4
pubmed: 19703247
Curr Med Chem. 2016;23(42):4773-4783
pubmed: 27881069
Antiviral Res. 2012 Feb;93(2):225-233
pubmed: 22179064
Pathogens. 2016 Dec 06;5(4):
pubmed: 27929449
Curr Geriatr Rep. 2017;6(1):26-33
pubmed: 29204334
J Pharm Biomed Anal. 2015;111:222-30
pubmed: 25910046
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Molecules. 2017 Aug 12;22(8):
pubmed: 28805687